Please login to the form below

Not currently logged in
Email:
Password:

Aimmune

This page shows the latest Aimmune news and features for those working in and with pharma, biotech and healthcare.

Nestlé and Seres announce new partnership for C.diff microbiome therapeutic

Nestlé and Seres announce new partnership for C.diff microbiome therapeutic

difficile infection,” added Greg Behar, CEO of Nestlé Health Science. In September 2020, Nestlé furthered its push into pharma with the acquisition of allergy specialist Aimmune Therapeutics in a deal worth ... Aimmune’s Palforzia became the first

Latest news

  • EU authorises Aimmune’s peanut allergy treatment Palforzia EU authorises Aimmune’s peanut allergy treatment Palforzia

    Approval in the EU comes nine months after US authorisation. Aimmune Therapeutics’ Palforzia has received approval from the European Commission (EC) for the treatment of a peanut allergy. ... Aimmune’s potential rival, DBV Technologies, has not had

  • Nestlé is set to acquire Aimmune in deal worth $2.6bn Nestlé is set to acquire Aimmune in deal worth $2.6bn

    Aimmune’s Palforzia therapy is the only FDA-approved peanut allergy drug. Nestlé has announced plans to acquire allergy specialist Aimmune Therapeutics in a deal worth $2.6bn, six months after ... Aimmune’s launch of Palforzia has been hampered by

  • FDA knocks back DBV’s peanut allergy therapy once again FDA knocks back DBV’s peanut allergy therapy once again

    Drug loses further ground to Aimmune's Palforzia. DBV Technologies’ struggle to get its peanut allergy therapy approved looks set to drag on, after the US Food and Drug Administration (FDA) ... Every month of delay gives Aimmune more time to extend its

  • Aimmune’s Palforzia is first peanut allergy drug cleared in US Aimmune’s Palforzia is first peanut allergy drug cleared in US

    Aimmune has also filed for approval in Europe, with a verdict due later this year. ... Analysts at GlobalData have suggested the market for peanut allergy products in eight major world markets could be worth $4.5bn in 2027, with Aimmune claiming a

  • Aimmune gets FDA panel backing for peanut allergy therapy Aimmune gets FDA panel backing for peanut allergy therapy

    Step closer to becoming first approved treatment. Aimmune’s AR101 has moved a step closer to becoming the first approved peanut allergy treatment in the US after an FDA advisory committee ... Aimmune has also been filed for approval in Europe, with a

More from news
Approximately 9 fully matching, plus 3 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...